1
Xiangdong Alan Wang, Li Qiang Sun, Sing Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Warren K Volles, February 7, 2006: US06995174 (89 worldwide citation)

Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


2
Paul Michael Scola, Jeffrey Allen Campbell, Ny Sin, Li Qiang Sun, Xiangdong Alan Wang: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, Warren K Volles, November 14, 2006: US07135462 (44 worldwide citation)

Hepatitis C virus inhibitors are disclosed having the general formula: wherein A, R2, R3, R′, B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


3
Xiangdong Alan Wang, Li Qiang Sun, Sing Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Warren K Volles, Pamela A Mingo, November 11, 2008: US07449479 (42 worldwide citation)

Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


4
Xiangdong Alan Wang, Li Qiang Sun, Sing Yuen Sit, Ny Sin, Paul Michael Scola, Yan Chen: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Warren K Volles, Pamela A Mingo, March 29, 2011: US07915291 (27 worldwide citation)

Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


5
Ny Sin, Brian Lee Venables, Li Qiang Sun, Sing Yuen Sit, Yan Chen, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, August 10, 2010: US07772180 (14 worldwide citation)

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


6
Yong Jin Wu, Li Qiang Sun, Huan He, Alexandre L Heureux: 1-aryl-2-hydroxyethyl amides as potassium channel openers. Bristol Myers Squibb Company, Aldo A Algieri, May 16, 2006: US07045551 (14 worldwide citation)

The present invention provides novel aryl hydroxyethyl amides and related derivatives having the general Formula I wherein R1, R2, R3, R4, R5, R6, R7 and A are as defined in the specification, or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof which are openers or activators ...


7
Xiangdong Alan Wang, Li Qiang Sun, Sing Yuen Sit, Ny Sin, Paul Michael Scola, Yan Chen: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Warren K Volles, Pamela A Mingo, October 30, 2012: US08299094 (11 worldwide citation)

Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


8
Alan Xiangdong Wang, Li Qiang Sun, Sing Yuen Sit, Ny Sin, Paul Michael Scola, Yan Chen: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, April 29, 2014: US08710229 (8 worldwide citation)

Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


9
Tao Wang, Annapurna Pendri, Zhongxing Zhang, Weixu Zhai, Guo Li, Samuel Gerritz, Paul Michael Scola, Li Qiang Sun, Qian Zhao, Eric Mull: Compounds for the treatment of hepatitis C. Bristol Myers Squibb Company, James Epperson, May 21, 2013: US08445490 (8 worldwide citation)

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.


10
Li Qiang Sun, Qian Zhao, Paul Michael Scola: Compounds for the treatment of hepatitis C. Bristol Myers Squibb Company, James Epperson, April 15, 2014: US08697706 (3 worldwide citation)

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.